Table 2 Univariate analysis of PFS and OS
mPFS (95% CI) | P | mOS (95% CI) | P | |
|---|---|---|---|---|
Age | ||||
< 56 | 4.07 (3.27-4.87) | 0.937 | 12.73 (9.46-15.99) | 0.453 |
≥ 56 | 4.70 (3.35-6.04) | 13.10 (10.10-16.09) | ||
Sex | ||||
Male | 4.27 (3.49-5.04) | 0.915 | 12.10 (10.43-13.76) | 0.072 |
Female | 4.43 (2.02-6.83) | 15.37 (11.48-19.25) | ||
Location | ||||
GEJ-cardia | 3.83 (1.16-6.49) | 0.926 | 14.03 (4.50-23.55) | 0.903 |
Body | 4.7 (3.95-5.44) | 12.37 (9.17-15.56) | ||
Antrum | 3.93 (0.47-4.38) | 14.17 (11.14-17.19) | ||
Differentiation | ||||
Well, moderately differentiated | 3.83 (3.49-4.16) | 0.530 | 12.10 (7.79-16.40) | 0.200 |
Poorly, signet ring cell type | 4.67 (3.77-5.56) | 13.13 (10.19-16.06) | ||
Lauren classification | ||||
Intestinal | 4.20 (3.29-5.10) | 0.479 | 13.10 (9.95-16.24) | 0.626 |
Diffuse | 4.27 (2.85-5.68) | 13.13 (9.62-16.63) | ||
Mixed | 4.93 (2.20-7.65) | 11.70 (2.55-20.84) | ||
Disease status | ||||
Recurrence after curative resection | 4.20 (3.13-5.26) | 0.714 | 12.10 (9.69-14.50) | 0.962 |
Initial metastasis | 4.43 (3.36-5.49) | 14.17 (11.10-17.23) | ||
Liver metastasis | ||||
Yes | 4.70 (2.89-6.50) | 0.537 | 14.03 (9.13-18.9) | 0.586 |
No | 4.27 (3.49-5.04) | 13.10 (10.06-16.14) | ||
Bone metastasis | ||||
Yes | 4.70 (0.82-8.57) | 0.368 | 9.77 (4.92-14.62) | 0.685 |
No | 4.27 (3.53-5.00) | 13.13 (10.76-15.49) | ||
Peritoneal metastasis | ||||
Yes | 4.57 (2.97-6.16) | 0.249 | 12.73 (9.04-16.41) | 0.887 |
No | 3.97 (3.15-4.78) | 13.10 (9.81-16.38) | ||
Chemotherapy response | ||||
CR, PR | 4.73 (3.12-6.33) | 0.341 | 11.43 (8.06-14.80) | 0.192 |
SD, PD | 3.97 (3.16-4.77) | 15.03 (12.33-17.72) | ||
Chemotherapeutic regimen | ||||
Paclitaxel/cisplatin | 4.07 (3.52-4.61) | 0.224 | 12.37 (10.23-14.50) | 0.221 |
Docetaxel/cisplatin | 6.50 (5.71-7.28) | 17.87 (14.42-21.31) | ||
No. of involved organs | ||||
1 | 3.97 (3.17-4.76) | 0.220 | 12.10 (9.15-15.04) | 0.570 |
2 | 4.73 (2.76-6.70) | 15.13 (10.11-20.14) | ||
≥ 3 | 7.07 (0.00-16.05) | 12.40 (9.91-14.88) | ||
TUBB3 | ||||
High-level expression | 3.63 (3.37-3.88) | 0.001 | 13.13 (9.88-16.37) | 0.769 |
Low-level expression | 6.67 (5.65-7.68) | 13.10 (8.83-17.36) | ||
ERCC1 | ||||
High-level expression | 3.77 (3.54-3.99) | 0.280 | 12.70 (9.45-15.94) | 0.916 |
Low-level expression | 5.23 (3.74-6.71) | 13.53 (10.10-16.95) |